Frost & Sullivan:India set to grab global biogenerics pie

Mumbai, Maharashtra, India, Monday, August 14, 2006 -- (Business Wire India) Frost & Sullivan's Healthcare Practice in South Asia and Middle East (http://www.healthcare.frost.com) will host an analyst briefing webinar on August 22, 2006, 11.30 am to 12.30 pm Indian Standard Time (GMT + 5.5 hrs).

The briefing provides an in-depth overview of the Indian Biogenerics Industry, focusing on key areas of opportunities - existing as well as emerging. It also outlines the changing demographics of the global biogenerics industry, the market opportunity arising thereof, vis-à-vis capabilities of the Indian biogenerics industry to tap this opportunity, through a detailed analysis of the drivers and restraints for the Indian Biogenerics market.

This briefing will largely benefit manufacturers, distributors, and marketing companies of recombinant biopharmaceuticals who wish to understand the dynamics of players from developing countries like India, defining the landscape of opportunities for collaborative ventures as well as for formulating strategies through anticipated developments.

The Indian pharmaceutical industry is one of the foremost industries worldwide and India is also one of the leading players in the chemical generics market. Recent years have witnessed the growing strength of Indian companies in the field of recombinant biopharmaceuticals. Rising drug development costs and increasing pressures on healthcare authorities worldwide to cut down healthcare expenditures, have tilted the dynamics in favor of relatively cost-effective Biogenerics, as opposed to branded biopharmaceuticals.

Regulatory authorities worldwide have been forced to significantly reform their policies so as to streamline the approval of Biogenerics. With existing capabilities in the pharmaceutical industry, and additional benefits like low-cost per transaction, Indian companies are all set to grab this opportunity and carve a niche in the global Biogenerics market.

"Major recombinant biopharmaceutical products are coming off-patent over the next few years, and with increasing efforts by regulatory authorities worldwide to streamline approval of Biogenerics, players from developing countries like India are all set to grab a significant share in the global Biogenerics pie." observes Industry Analyst (Biotech & Life Sciences) Dr. Jayashree Mapari.

Those interested in participating in the interactive webinar can also log on to http://w.on24.com/r.htm?e=26465&s=1&k=C1B58262212FCFE548686CF6849E752F and register for this analyst briefing.

Alternatively, one can send an email to Surbhi Dedhia, Corporate Communications at sdedhia@frost.com with the following information: full name, company name, title, telephone number, e-mail address, city, state and country. The registration details will be emailed to you upon receipt of the above information.

About Frost & Sullivan: Frost & Sullivan, a global growth consulting company has been partnering with clients to support the development of innovative strategies for more than 45 years The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com

For press backgrounder on Frost & Sullivan click here

Media contact details

Surbhi Dedhia, Corporate Communications, Frost & Sullivan, +91 (022) 4001 3431, sdedhia@frost.com